Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice

Background—Atherosclerosis is a complex vascular inflammatory disease. Low-dose aspirin is a mainstay in the prevention of vascular complications of atherosclerosis. We wished to determine the effect of low-dose aspirin on vascular inflammation, plaque composition, and atherogenesis in LDL receptor–deficient mice fed a high fat diet. Methods and Results—In LDL receptor–deficient mice fed a high fat diet compared with control mice, low-dose aspirin induced a significant decrease in circulating levels and vascular formation of soluble intercellular molecule-1, monocyte chemoattractant protein-1, tumor necrosis factor-&agr;, interleukin-12p 40, without affecting lipid levels. This was associated with significant reduction of the nuclear factor &kgr;B activity in the aorta. Low-dose aspirin also significantly reduced the extent of atherosclerosis. Finally, aortic vascular lesions of the aspirin-treated animals showed 57% reduction (P <0.05) in the amount of macrophage cells, 77% increase in smooth muscle cells (P <0.05), and 23% increase in collagen (P <0.05). Conclusions—Our results suggest that in murine atherosclerosis, low-dose aspirin suppresses vascular inflammation and increases the stability of atherosclerotic plaques, both of which, together with its antiplatelet activity, contribute to its antiatherogenic effect. We conclude that low-dose aspirin might be rationally evaluated in the progression and evolution of human atherosclerotic plaque.

[1]  G. FitzGerald,et al.  Lipid Peroxidation and Platelet Activation in Murine Atherosclerosis , 2001, Circulation.

[2]  P. Mills,et al.  The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. , 2001, Journal of the American College of Cardiology.

[3]  W. Kisiel,et al.  Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. , 2001, The Journal of clinical investigation.

[4]  J. Schroeder,et al.  Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. , 2001, Blood.

[5]  G. FitzGerald,et al.  Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Rader,et al.  Reduction of Isoprostanes and Regression of Advanced Atherosclerosis by Apolipoprotein E* , 2001, The Journal of Biological Chemistry.

[7]  S. Han,et al.  Effect of acetylsalicylic acid on endogenous IκB kinase activity in lung epithelial cells , 2001 .

[8]  J. Joven,et al.  The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. , 2000, Life sciences.

[9]  G. FitzGerald,et al.  Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. , 2000, Blood.

[10]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[11]  R. Cohen,et al.  The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[12]  C Warlow,et al.  Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. , 2000, Stroke.

[13]  M. Matsuhisa,et al.  Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. , 2000, Thrombosis research.

[14]  P. Groot,et al.  Chemokines and atherosclerosis. , 1999, Atherosclerosis.

[15]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[16]  P. Libby,et al.  Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. , 1999, Circulation.

[17]  S. L. Murphy,et al.  Deaths: final data for 1996. , 1998, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[18]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[19]  P. Libby,et al.  Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. , 1998, The American journal of medicine.

[20]  C. Serhan Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? , 1997, Prostaglandins.

[21]  R. Knuechel,et al.  Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. , 1996, The Journal of clinical investigation.

[22]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[23]  T. Collins Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[24]  H. Hecker,et al.  Dose‐Dependent Effect of Aspirin on Carotid Atherosclerosis , 1993, Circulation.

[25]  G. FitzGerald,et al.  Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. , 1991, The New England journal of medicine.

[26]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[27]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .